Titre :

Expression of functional soluble human leucocyte antigen-G molecules in lymphoproliferative disorders.

Auteur(s) :

Sebti, Yasmine [Auteur]
Récepteurs nucléaires, maladies cardiovasculaires et diabète - U 1011 [RNMCD]
Le Maux, Amélie [Auteur]
Gros, Frédéric [Auteur]
Immunologie et chimie thérapeutiques [ICT]
de Guibert, Sophie [Auteur]
Service d'hématologie clinique
Pangault, Céline [Auteur]
Microenvironnement et cancer [MiCa]
Service d'Hématologie, Immunologie et de Thérapie Cellulaire [HITC]
Rouas-Freiss, Nathalie [Auteur]
Service de Recherche en Hémato-Immunologie [SRHI - UMR_E 05]
Bernard, Marc [Auteur]
Laboratoire Hubert Curien [LabHC]
Amiot, Laurence [Auteur]
Service d'hématologie clinique
Signalisation et Réponses aux Agents Infectieux et Chimiques [SeRAIC]

Titre de la revue :

British Journal of Haematology

Pagination :

202-12

Éditeur :

Wiley

Date de publication :

2007-07

ISSN :

0007-1048

Mot(s)-clé(s) en anglais :

soluble human leucocyte antigen-G
lymphoproliferative disorders
immunosuppression
chronic lymphocytic leukaemia
non-Hodgkin lymphoma

Discipline(s) HAL :

Sciences du Vivant [q-bio]/Biochimie, Biologie Moléculaire

Résumé en anglais : [en]

Membrane-bound and soluble human leucocyte antigen-G (sHLA-G) molecules display immunotolerant properties favouring tumour cell escape from immune surveillance. sHLA-G molecules have been detected in several tumour ...
Lire la suite >Membrane-bound and soluble human leucocyte antigen-G (sHLA-G) molecules display immunotolerant properties favouring tumour cell escape from immune surveillance. sHLA-G molecules have been detected in several tumour pathologies; this study aimed to evaluate sHLA-G expression in lymphoproliferative disorders. sHLA-G plasma level was significantly increased in 110 of 178 newly diagnosed lymphoid proliferations cases i.e. 59% of chronic lymphocytic leukaemia, 65% of B non-Hodgkin lymphomas (NHL) and 58% of T-NHL. To assess the mechanisms involved in this secretion, the differential effect of cytokines was tested in in vitro cultures of NHL cells. A significant induction of sHLA-G level was shown in T-NHL in contrast with B-NHL and normal equivalent cells, after cytokine stimulation with (i) interferongamma (IFNgamma), interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor, (ii) IL-10 and (iii) transforming growth factor beta. An impact of microenvironment on sHLA-G expression was found in B-NHL as shown by the in vitro effect of addition of normal monocytes. Finally, a functional effect of sHLA-G molecules purified from pathologic plasma was demonstrated by their strong capacity to inhibit T-cell proliferation at concentrations currently observed during these disorders. These results suggest that functional sHLA-G molecules are upregulated in lymphoproliferative disorders which can support their potential immunomodulatory role during this pathology.Lire moins >

Langue :

Anglais

Vulgarisation :

Non

Collections :

• Récepteurs nucléaires, Maladies Cardiovasculaires et Diabète (RNMCD) - U1011

Source :

Harvested from HAL